Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa.

Authors :: Hunjan MK
Bardhan A
Harper N
Langman G
Ajayi B
Suresh V
Heagerty AHM
Source :: Clinical and experimental dermatology [Clin Exp Dermatol] 2022 Aug; Vol. 47 (8), pp. 1588-1590. Date of Electronic Publication: 2022 Jun 09.
Publication Year :: 2022
Abstract: We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.<br /> (© 2022 British Association of Dermatologists.)

Subjects :: Antibodies, Monoclonal
Humans
Rituximab therapeutic use
Antineoplastic Agents
Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica complications
Epidermolysis Bullosa Dystrophica drug therapy
Glomerulonephritis, IGA complications
Glomerulonephritis, IGA drug therapy

Full Text Access

Tools